Buy $5,000 of Cochlear shares today and it could be worth this much in 12 months

Find out what brokers tip for this ASX healthcare stock next.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Ltd (ASX: COH) shares are up around 1% and changing hands at $141.96 a piece, at the time of writing on Wednesday morning.

The latest increase comes off the back of a 8% share price hike on Tuesday, following the company's latest FY26 results announcement.

Cochlear posted a 2% increase in sales revenue and a 22% decrease in its underlying net profit, which came in right at the top end of guidance.

There were some significant positives though. Cochlear's operating cash flow surged $130 million to $368 million, while free cash flow also improved substantially. The company also continued to invest aggressively in research and development, lifting R&D spending 15% as it accelerated work on its product pipeline.

Clearly investors were pleased with the results and its shares have kept climbing higher.

It's great news for the stock after Cochlear shares suffered a huge 41% one-day crash in late-April after the company downgraded its guidance figures. 

Since hitting a 10-year low of just $90 per share in late-April, Cochlear shares have now rebounded 52%. There is still a long way to go, however. The shares are now down around 46% for the year to date and are roughly 52% lower than this time last year.

The question now is, can Cochlear shares keep climbing higher?

A woman leans forward with her hand behind her ear, as if trying to hear information.

Image source: Getty Images

What do analysts tip next for Cochlear shares?

It's possible that brokers and analysts could revise their stance on Cochlear shares in coming days, following the company's FY26 update yesterday.

But at the time of writing, it looks like the experts are still on the fence about the outlook for the hearing implant company's shares over the next 12 months.

Many are now uncertain that Cochlear shares can stage a meaningful recovery over the next 12 months. And some believe the shares are now above fair value.

Market Index data shows the majority of brokers have a hold rating on Cochlear shares. The $116.08 average target price now implies a potential 18% downside from the current trading price.

TradingView data shows something similar, although the figures are a little less pessimistic. Again, the majority of analysts have a hold rating on the shares. The $139.21 average target price implies a potential 2% downside over the next 12 months, at the time of writing.

So, if I invest $5,000 into Cochlear shares today, what could it be worth in 12 months?

These forecasts suggest that a $5,000 investment into Cochlear shares today, could fall to somewhere around $4,100 to $4,900 by this time next year. That implies a loss of up to $900.

What could drive Cochlear shares higher?

It's been a difficult year for the medical hearing implant device company. Cochlear has suffered from a number of strong headwinds, including a sector-wide rotation away from ASX healthcare shares this year. 

Looking ahead, I still see Cochlear as a strong, globally dominant business with its long-term outlook intact. I think the steep sell-offs this year were overdone, and that the share price could quietly keep climbing higher.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

cochlear happy, share price rise, up, increase
Healthcare Shares

Cochlear share price rebounds 53% from 10-year low: Can it keep climbing?

The shares are still down 47% for the year to date.

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Two broker upgrades put CSL shares back in focus

CSL is back on the radar after two broker upgrades.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Could this ASX biotech really jump more than 150%? One broker thinks so

A key clinical trial could be a big catalyst for this company.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Cochlear vs Pro Medicus: Which beaten-down ASX healthcare share is the better buy today?

We compare Cochlear and Pro Medicus after major share price declines. See which ASX healthcare stock I’d lean towards today.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Are Telix shares a buy after its big US FDA news?

Telix announced some big news this week.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

These 2 ASX healthcare shares just jumped up to 15%. Here's why

These high-beta healthcare stocks swing hard on catalysts.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Is the CSL share price heading to $200?

The healthcare giant is no longer dirt cheap, so I think further gains will need stronger support from earnings.

Read more »

Two brokers pointing and analysing a share price.
Healthcare Shares

CSL shares have surged over 25%. Do brokers see more upside?

CSL shares may keep climbing, but can earnings catch up?

Read more »